Cargando…
Ependyma: a new target for autoantibodies in neuromyelitis optica?
Neuromyelitis optica (NMO) is an autoimmune demyelinating disease of the central nervous system characterized by the presence of autoantibodies (called NMO-IgG) targeting aquaporin-4. Aquaporin-4 is expressed at the perivascular foot processes of astrocytes, in the glia limitans, but also at the epe...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897195/ https://www.ncbi.nlm.nih.gov/pubmed/36751497 http://dx.doi.org/10.1093/braincomms/fcac307 |
_version_ | 1784882201675956224 |
---|---|
author | Bigotte, Maxime Gimenez, Marie Gavoille, Antoine Deligiannopoulou, Adamantia El Hajj, Aseel Croze, Severine Goumaidi, Abdelghafar Malleret, Gael Salin, Paul Giraudon, Pascale Ruiz, Anne Marignier, Romain |
author_facet | Bigotte, Maxime Gimenez, Marie Gavoille, Antoine Deligiannopoulou, Adamantia El Hajj, Aseel Croze, Severine Goumaidi, Abdelghafar Malleret, Gael Salin, Paul Giraudon, Pascale Ruiz, Anne Marignier, Romain |
author_sort | Bigotte, Maxime |
collection | PubMed |
description | Neuromyelitis optica (NMO) is an autoimmune demyelinating disease of the central nervous system characterized by the presence of autoantibodies (called NMO-IgG) targeting aquaporin-4. Aquaporin-4 is expressed at the perivascular foot processes of astrocytes, in the glia limitans, but also at the ependyma. Most studies have focused on studying the pathogenicity of NMO-IgG on astrocytes, and NMO is now considered an astrocytopathy. However, periependymal lesions are observed in NMO suggesting that ependymal cells could also be targeted by NMO-IgG. Ependymal cells regulate CSF-parenchyma molecular exchanges and CSF flow, and are a niche for sub-ventricular neural stem cells. Our aim was to examine the effect of antibodies from NMO patients on ependymal cells. We exposed two models, i.e. primary cultures of rat ependymal cells and explant cultures of rat lateral ventricular wall whole mounts, to purified IgG of NMO patients (NMO-IgG) for 24 hours. We then evaluated the treatment effect using immunolabelling, functional assays, ependymal flow analysis and bulk RNA sequencing. For each experiment, the effects were compared with those of purified IgG from a healthy donors and non-treated cells. We found that: (i) NMO-IgG induced aquaporin-4 agglomeration at the surface of ependymal cells and induced cell enlargement in comparison to controls. In parallel, it induced an increase in gap junction connexin-43 plaque size; (ii) NMO-IgG altered the orientation of ciliary basal bodies and functionally impaired cilia motility; (iii) NMO-IgG activated the proliferation of sub-ventricular neural stem cells; (iv) treatment with NMO-IgG up-regulated the expression of pro-inflammatory cytokines and chemokines in the transcriptomic analysis. Our study showed that NMO-IgG can trigger an early and specific reactive phenotype in ependymal cells, with functional alterations of intercellular communication and cilia, activation of sub-ventricular stem cell proliferation and the secretion of pro-inflammatory cytokines. These findings suggest a key role for ependymal cells in the early phase of NMO lesion formation. |
format | Online Article Text |
id | pubmed-9897195 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-98971952023-02-06 Ependyma: a new target for autoantibodies in neuromyelitis optica? Bigotte, Maxime Gimenez, Marie Gavoille, Antoine Deligiannopoulou, Adamantia El Hajj, Aseel Croze, Severine Goumaidi, Abdelghafar Malleret, Gael Salin, Paul Giraudon, Pascale Ruiz, Anne Marignier, Romain Brain Commun Original Article Neuromyelitis optica (NMO) is an autoimmune demyelinating disease of the central nervous system characterized by the presence of autoantibodies (called NMO-IgG) targeting aquaporin-4. Aquaporin-4 is expressed at the perivascular foot processes of astrocytes, in the glia limitans, but also at the ependyma. Most studies have focused on studying the pathogenicity of NMO-IgG on astrocytes, and NMO is now considered an astrocytopathy. However, periependymal lesions are observed in NMO suggesting that ependymal cells could also be targeted by NMO-IgG. Ependymal cells regulate CSF-parenchyma molecular exchanges and CSF flow, and are a niche for sub-ventricular neural stem cells. Our aim was to examine the effect of antibodies from NMO patients on ependymal cells. We exposed two models, i.e. primary cultures of rat ependymal cells and explant cultures of rat lateral ventricular wall whole mounts, to purified IgG of NMO patients (NMO-IgG) for 24 hours. We then evaluated the treatment effect using immunolabelling, functional assays, ependymal flow analysis and bulk RNA sequencing. For each experiment, the effects were compared with those of purified IgG from a healthy donors and non-treated cells. We found that: (i) NMO-IgG induced aquaporin-4 agglomeration at the surface of ependymal cells and induced cell enlargement in comparison to controls. In parallel, it induced an increase in gap junction connexin-43 plaque size; (ii) NMO-IgG altered the orientation of ciliary basal bodies and functionally impaired cilia motility; (iii) NMO-IgG activated the proliferation of sub-ventricular neural stem cells; (iv) treatment with NMO-IgG up-regulated the expression of pro-inflammatory cytokines and chemokines in the transcriptomic analysis. Our study showed that NMO-IgG can trigger an early and specific reactive phenotype in ependymal cells, with functional alterations of intercellular communication and cilia, activation of sub-ventricular stem cell proliferation and the secretion of pro-inflammatory cytokines. These findings suggest a key role for ependymal cells in the early phase of NMO lesion formation. Oxford University Press 2022-11-30 /pmc/articles/PMC9897195/ /pubmed/36751497 http://dx.doi.org/10.1093/braincomms/fcac307 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Bigotte, Maxime Gimenez, Marie Gavoille, Antoine Deligiannopoulou, Adamantia El Hajj, Aseel Croze, Severine Goumaidi, Abdelghafar Malleret, Gael Salin, Paul Giraudon, Pascale Ruiz, Anne Marignier, Romain Ependyma: a new target for autoantibodies in neuromyelitis optica? |
title | Ependyma: a new target for autoantibodies in neuromyelitis optica? |
title_full | Ependyma: a new target for autoantibodies in neuromyelitis optica? |
title_fullStr | Ependyma: a new target for autoantibodies in neuromyelitis optica? |
title_full_unstemmed | Ependyma: a new target for autoantibodies in neuromyelitis optica? |
title_short | Ependyma: a new target for autoantibodies in neuromyelitis optica? |
title_sort | ependyma: a new target for autoantibodies in neuromyelitis optica? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897195/ https://www.ncbi.nlm.nih.gov/pubmed/36751497 http://dx.doi.org/10.1093/braincomms/fcac307 |
work_keys_str_mv | AT bigottemaxime ependymaanewtargetforautoantibodiesinneuromyelitisoptica AT gimenezmarie ependymaanewtargetforautoantibodiesinneuromyelitisoptica AT gavoilleantoine ependymaanewtargetforautoantibodiesinneuromyelitisoptica AT deligiannopoulouadamantia ependymaanewtargetforautoantibodiesinneuromyelitisoptica AT elhajjaseel ependymaanewtargetforautoantibodiesinneuromyelitisoptica AT crozeseverine ependymaanewtargetforautoantibodiesinneuromyelitisoptica AT goumaidiabdelghafar ependymaanewtargetforautoantibodiesinneuromyelitisoptica AT malleretgael ependymaanewtargetforautoantibodiesinneuromyelitisoptica AT salinpaul ependymaanewtargetforautoantibodiesinneuromyelitisoptica AT giraudonpascale ependymaanewtargetforautoantibodiesinneuromyelitisoptica AT ruizanne ependymaanewtargetforautoantibodiesinneuromyelitisoptica AT marignierromain ependymaanewtargetforautoantibodiesinneuromyelitisoptica |